What are SPARC antibodies?
Anti-SPARC antibodies are immunoglobulins that specifically recognize and bind SPARC, also known as osteonectin, in humans. In research applications, these antibodies are used to detect SPARC in tissue samples, cell lysates, and cultured cells. SPARC regulates cell growth through interactions with the extracellular matrix and cytokines, binding calcium, copper, several types of collagen, albumin, thrombospondin, and platelet-derived growth factor. Detecting SPARC supports research into tissue remodeling and fibrosis as well as its role in tumor stroma interactions and cancer progression.
Catalog highlights and purchasing considerations
About the Biocompare SPARC antibody catalog
The Biocompare antibody search tool lists anti-SPARC antibodies from a range of suppliers, spanning unconjugated and fluorophore- or enzyme-conjugated formats. Listings may also appear under the alternate name osteonectin. Western blot is the most common validated application among these listings, followed by immunohistochemistry and ELISA. Several SPARC antibodies mentioned here have been cited across a range of tissue biology research, including corneal epithelial wound healing through β-catenin and c-Met signaling, tubulointerstitial fibrosis via the CBP-DOT1L pathway, and perineural invasion in pancreatic ductal adenocarcinoma.
Considerations when choosing a SPARC antibody for research
Confirm that the antibody's intended target is accurate, as many genes carry synonym symbols that can create ambiguity across suppliers. Specificity should be verified against the immunogen sequence or region listed on the product datasheet, since antibodies raised against different epitopes of the same protein can behave differently across applications. Beyond specificity, several target-related attributes can affect antibody binding, including subcellular location, extracellular and cytoplasmic domain boundaries for membrane-associated targets, tissue specificity, post-translational modifications, and the presence of additional isoforms or disease-associated variants. In parallel, antibody-specific selection criteria warrant consideration, including clonality (monoclonal versus polyclonal), host species, species reactivity, and conjugate or label choice suited to the detection method. Supplier validation data, such as western blot bands at the expected molecular weight, immunohistochemistry staining patterns consistent with known tissue distribution, and knockout or knockdown controls, should also be carefully reviewed before purchase.